002430 杭氧集团股份有限公司 证券代码：002430 证券简称：杭氧股份 杭氧集团股份有限公司投资者关系活动记录表 编号：20250410 ~ 2 ~ 002430 杭氧集团股份有限公司 | 答：感谢您的关注！公司围绕空分设备成套业务建立了完整的制造产 | | --- | | 业链配套协同体系，并根据与空分设备的关联紧密度关系，形成了全 | | 资、控股、参股等不同股权类型的制造子公司。各子公司围绕提升空 | | 分设备的竞争力积极发挥专业与协同作用。公司将立足业务发展需要 | | 实施强链、补链、延链计划，并对现有配套体系根据竞争力情况适时 | | 实施进退流转，以确保产业链的安全稳定与竞争力。 | | 问题八：高管您好，请问贵公司本期财务报告中，盈利表现如何？谢 | | 谢。 | | 答：如您问的本期指 2024 年，盈利状况请详见年报。如指本年度第 | | 一季度，相关经营情况请等待公告。谢谢！ | | 问题九：请问下游行业的不景气是否影响到公司的收款？坏账情况如 | | 何？ | | 答：您好。公司应收款主要分两部分：1、设备部分，设备 85%-90%在 | | 在发货之前支付，10%-15%为 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 杭氧集团股份有限公司（以下简称"公司"或"本公司"）于2025年3月26日 召开第八届董事会第二十次会议，审议通过了《关于召开2024年度股东大会的议 案》，决定于2025年4月18日下午14:30召开2024年度股东大会，具体内容详见公司 于2025年3月28日在《证券时报》、《上海证券报》和巨潮资讯网（www.cninfo.com.cn） 披露的《关于召开2024年度股东大会的通知公告》（公告编号：2025-020）。 现因可转换公司债券相关提案仍需完善，公司于2025年4月10日召开第八届董 事会第二十一次（临时）会议，审议通过了《关于取消2024年度股东大会部分提 案的议案》，董事会同意2024年度股东大会取消审议可转换公司债券相关提案： 《关于公司符合向不特定对象发行可转换公司债券条件的提案》、《关于公司向 不特定对象发行可转换公司债券方案的提案》、《关于公司向不特定对象发行可 转换公司债券预案的提案》、《关于公司向不特定对象发行可转换公司债券的论 证分析报告的提案》、《关于向不特定对象发行可转换公司债 ...

| | | 债券代码：127064 债券简称：杭氧转债 杭氧集团股份有限公司 《关于公司向不特定对象发行可转换公司债券预案的提案》、《关于公司向不特定 对象发行可转换公司债券的论证分析报告的提案》、《关于向不特定对象发行可转 换公司债券募集资金运用的可行性分析报告的提案》、《关于向不特定对象发行可 转换公司债券摊薄即期回报、填补措施及相关主体承诺的提案》、《关于制定<可转 换公司债券持有人会议规则（2025年2月）>的提案》、《关于前次募集资金使用情 况报告的提案》、《关于提请股东大会授权董事会及董事会授权人士全权办理本次 向不特定对象发行可转换公司债券具体事宜的提案》。 第八届董事会第二十一次（临时）会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 杭氧集团股份有限公司（以下简称"公司"或"本公司"）于2025年4月10日以通讯 会议方式召开了第八届董事会第二十一次（临时）会议，根据《公司章程》、《董 事会议事规则》等的有关规定并经全体董事一致同意，本次董事会会议豁免通知时 限的要求。会议由公司董事长郑伟先生主持，应参加会议的董事9名，实际参加会 ...

股票代码：002430 股票简称：杭氧股份 公告编号：2025-032 转债代码：127064 转债简称：杭氧转债 杭氧集团股份有限公司 关于控股股东增持公司股份计划的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 2、本次增持计划可能存在因资本市场发生变化或目前尚无法预判的其他因素， 导致本次增持计划实施无法达到预期的风险。 公司于 2025 年 4 月 9 日收到公司控股股东杭氧控股出具的《关于增持上市公司 杭氧股份股票的函》，现将相关情况公告如下： 一、计划增持主体的基本情况 1、本次增持主体为杭氧控股，截至本次增持计划实施前，杭氧控股持有公司股 份 524,754,485 股，占公司当前总股本的比例为 53.33%。 2、杭氧控股在本次公告前 12 个月内未披露增持公司股份的计划；在本次公告前 6 个月内不存在减持公司股份的情况。 二、本次增持计划的主要内容 1、本次拟增持股份的目的：基于对公司长期投资价值的认可及未来发展前景的 信心，维护广大投资者利益，支持公司持续、稳定、健康发展。 2、本次拟增持股份的种类和方式：A 股，通过二级市场增持，包 ...

因主营业务稳健发展及海外市场拓展成效显著，杭氧股份（002430.SZ）近期相继受到了15家券商关注 及发布点评研报，显示出市场对其业务表现和发展前景的高度关注。其中，光大证券在点评公司2024年 年报时指出，尽管面临挑战，杭氧股份在大空分设备和海外市场拓展方面持续取得进展，并继续开拓新 的气体业务领域。 研报指出，公司设备营收增长明显，2024年公司空分设备业务收入达到45.25亿元，同比增长6.77%，订 单量充足，合同负债上升至31.76亿元，显示出公司在大型项目和海外市场的积极拓展成果。其中公司 空分石化设备全年累计订货额55.12亿元。 此外，乙烯冷箱、液氮洗冷箱等领域继续保持国内领先地位，石化装备全年合同额达历史最高的8.41亿 元，创历史新高。在大空分项目和海外市场，公司拓展取得成效，全年签订大中型空分设备22套，其中 6万以上特大型空分12套，全年外贸合同额达9.33亿元，占比近17%，自主研发的先进技术在墨西哥5万 Nm3/h空分项目中应用。 券商研报中指出，公司产品结构的变化对设备制造业务的毛利率构成压力，降至27.71%，同比下降2.19 个百分点。特别是在零售气价格低迷的情况下，气体业 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][6] Core Views - The company achieved a stable revenue growth of 3.06% year-on-year, reaching 13.716 billion yuan in 2024, while the net profit attributable to shareholders decreased by 24.15% to 922 million yuan [1][5] - The gas business faced pressure due to a sluggish retail gas market, resulting in a 1.15% decline in revenue to 8.1 billion yuan [2] - The equipment sales business saw a revenue increase of 7.22% to 5.065 billion yuan, with a total order amount of 5.512 billion yuan for air separation equipment [3] - The company is actively expanding its gas application fields, with significant increases in sales of electronic-grade hydrogen and helium, growing by 88.31% and 92.87% respectively [4] Summary by Sections Revenue and Profitability - In 2024, the company reported operating revenue of 13.716 billion yuan, a 3.06% increase from the previous year, while the net profit attributable to shareholders was 922 million yuan, down 24.15% [1] - The gross margin was 20.85%, a decrease of 2.06 percentage points year-on-year, and the net margin was 7.23%, down 2.35 percentage points [1] Gas Business Performance - The gas segment generated revenue of 8.1 billion yuan, a decline of 1.15% year-on-year, with a gross margin of 16.17%, down 2.52 percentage points [2] - The company signed six new gas investment projects in 2024, with a total oxygen production capacity of approximately 650,000 Nm³/h [2] Equipment Sales - The equipment sales segment achieved revenue of 5.065 billion yuan, a 7.22% increase year-on-year, with a gross margin of 27.71%, down 2.14 percentage points [3] - The total order amount for air separation equipment reached 5.512 billion yuan, with 22 sets of large and medium-sized equipment signed [3] Research and Development - The company invested 449 million yuan in R&D, representing a 3.27% R&D expense ratio [4] - The sales of medical oxygen reached 45,000 tons, and the first medical onsite gas production project was put into operation [4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company achieved an annual revenue of 13.716 billion yuan in 2024, representing a year-on-year increase of 3.06%, while the net profit attributable to shareholders was 922 million yuan, a decrease of 24.15% year-on-year [2][4] - In Q4 2024, the company reported a revenue of 3.364 billion yuan, down 4.68% year-on-year, and a net profit of 247 million yuan, down 32.26% year-on-year [2][4] - The company continues to expand its large air separation and overseas markets, achieving significant results in new gas business areas [10] Summary by Sections Financial Performance - The company’s total revenue for 2024 was 13.716 billion yuan, with a gross profit of 2.860 billion yuan, resulting in a gross margin of 21% [14] - The gas business revenue was 8.100 billion yuan, a decline of 1.15% year-on-year, with a gross margin of 16.17%, down 2.52 percentage points [10] - The equipment manufacturing business generated revenue of 4.525 billion yuan, an increase of 6.77% year-on-year, but the gross margin decreased to 27.71%, down 2.14 percentage points [10] Business Development - The company signed six new gas investment projects in 2024, with a total oxygen production capacity of approximately 650,000 Nm³/h [10] - The company’s liquid sales reached 2.82 million tons, exceeding the previous year's 2.40 million tons [10] - The company is actively developing new gas applications, including electronic gases, medical gases, and high-purity gases, with significant sales growth in pipeline electronic-grade hydrogen and helium [10] Future Outlook - For 2025, the company expects gas prices to stabilize, with ongoing project implementations and anticipated steady growth in gas sales [10] - The company forecasts net profits attributable to shareholders of 1.08 billion yuan, 1.30 billion yuan, and 1.50 billion yuan for 2025, 2026, and 2027, respectively, corresponding to PE ratios of 19, 16, and 14 times [10]

Core Viewpoint - The company reported a decline in net profit for 2024, attributed to macroeconomic factors and a sluggish liquid market, despite a slight increase in revenue [1][2]. Financial Performance - In 2024, the company achieved operating revenue of 13.716 billion yuan, a year-on-year increase of 3.06% - The net profit attributable to shareholders was 922 million yuan, a year-on-year decrease of 24.15% - The non-recurring net profit was 861 million yuan, a year-on-year decrease of 23.41% - In Q4 2024, the operating revenue was 3.364 billion yuan, a year-on-year decrease of 4.68% - The net profit attributable to shareholders in Q4 was 247 million yuan, a year-on-year decrease of 32.26% - The non-recurring net profit in Q4 was 235 million yuan, a year-on-year decrease of 26.52% [1]. Profitability Analysis - The company's gross margin and net margin for 2024 were 20.85% and 7.23%, respectively, down by 2.06 percentage points and 2.35 percentage points year-on-year - In Q4 2024, the gross margin was 22.22%, up by 3.06 percentage points, while the net margin was 7.57%, down by 3.12 percentage points - The goodwill impairment in 2024 amounted to 65 million yuan, negatively impacting the net margin [2]. Business Segment Performance - Gas sales revenue for 2024 was 8.1 billion yuan, a year-on-year decrease of 1.15%, with a gross margin of 16.17%, down by 2.52 percentage points - Revenue from air separation equipment was 4.525 billion yuan, a year-on-year increase of 6.77%, with a gross margin of 29.88%, down by 1.58 percentage points - Engineering contracting revenue was 186 million yuan, a year-on-year increase of 108.22% - Other business revenue was 366 million yuan, a year-on-year increase of 21.07% [2]. Business Expansion and Internationalization - The gas business saw an increase in installed capacity, with six new gas investment projects signed in 2024, adding a total oxygen production capacity of approximately 650,000 Nm³/h - The company sold 2.82 million tons of liquid gas in 2024 and is actively developing electronic gases, medical gases, new energy gases, and high-purity gases - The company plans to establish a joint venture to develop the semiconductor gas market, enhancing its special gas product matrix [3]. Order and Contract Performance - The order amount for air separation and petrochemical equipment in 2024 was 5.512 billion yuan, with 22 large and medium-sized air separation units signed - The foreign trade contract amount reached 933 million yuan, accounting for nearly 17% of total contracts - The petrochemical equipment contract amount reached a historical high of 841 million yuan [3]. Profit Forecast and Valuation - The company is expected to achieve net profits attributable to shareholders of 1.046 billion yuan, 1.176 billion yuan, and 1.335 billion yuan for 2025, 2026, and 2027, respectively - The estimated EPS for these years is 1.06 yuan, 1.20 yuan, and 1.36 yuan per share - A valuation range of 25.50 to 27.63 yuan per share is suggested for 2025, based on a PE ratio of 24-26 times [4].

Investment Rating - The investment rating for the company is "Outperform the Market" [2][10][20] Core Views - The company reported a revenue of 13.716 billion yuan in 2024, a year-on-year increase of 3.06%, while the net profit attributable to shareholders was 922 million yuan, a decrease of 24.15% year-on-year [5][6] - The company's profitability is under pressure primarily due to macroeconomic factors and a sluggish liquid market, with a gross margin of 20.85% and a net margin of 7.23% in 2024 [6][12] - The gas sales revenue was 8.1 billion yuan, down 1.15% year-on-year, while the revenue from air separation equipment increased by 6.77% to 4.525 billion yuan [6][18] Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 3.364 billion yuan, down 4.68% year-on-year, and a net profit of 247 million yuan, down 32.26% year-on-year [5][6] - The company expects a recovery in gas sales and profitability in the coming years, with projected revenues of 16.04 billion yuan in 2025 and 17.49 billion yuan in 2026 [8][23] Business Segments - The gas business continues to expand, with six new gas investment projects signed in 2024, increasing the total oxygen production capacity to 3.5 million Nm³/h [7][12] - The equipment business is accelerating its internationalization, with a record high order amount of 5.512 billion yuan for air separation equipment in 2024 [7][19] Market Outlook - The company is positioned as a leader in the industrial gas sector, with a strong cash flow and the ability to penetrate various downstream industries [20][22] - The projected earnings per share (EPS) for 2025 is 1.06 yuan, with a reasonable valuation range of 25.50 to 27.63 yuan per share based on a PE ratio of 24-26 times [10][20]

股票代码：002430 股票简称：杭氧股份 公告编号：2025-031 转债代码：127064 转债简称：杭氧转债 杭氧集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： "杭氧转债"（转债代码：127064）转股期为2022年11月25日至2028年5月18 日，目前转股价格为人民币26.89元/股。 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第15号——可转换公司债券》的有关规定，杭氧集团股份有限公司（以下简 称"公司"）将2025年第一季度可转换公司债券（以下简称"可转债"）转股及公司 股份变动的情况公告如下： 一、 可转债发行上市概况 分配。本次权益分配实施后，"杭氧转债"转股价格调整为27.88元/股，调整后的 转股价格自2023年5月8日起生效。 年度中期利润分配。本次权益分配实施后，"杭氧转债"转股价格调整为27.68元/ 股，调整后的转股价格自2023年9月26日起生效。 （一）可转换公司债券发行情况 中国证券监督管理委员会《关于核准杭州制氧机集团股份有限公司公开发行 可转换公司债券的批复 ...